Athira Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business HighlightsGlobeNewsWire • 03/25/21
Athira Pharma Announces Appointment of Barbara Kosacz to its Board of DirectorsGlobeNewsWire • 03/08/21
Athira Pharma to Present at H.C. Wainwright & Co. Global Life Sciences ConferenceGlobeNewsWire • 03/02/21
Athira Pharma Announces Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 02/10/21
Athira Pharma to Present at the 39th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/07/21
Athira Pharma Announces Appointment of Kelly A. Romano to its Board of DirectorsGlobeNewsWire • 12/14/20
Athira Pharma wins $15M grant for clinical trial of Alzheimer's drug from National Institute on AgingGeekWire • 12/08/20
Athira Pharma Awarded $15 Million Grant from National Institute on Aging to Support ACT-AD Clinical Trial in Alzheimer's DiseaseGlobeNewsWire • 12/08/20
Athira Pharma Announces Initiation of Patient Dosing for ACT-AD Clinical Trial of ATH-1017, Small Molecule HGF/MET Activator, for Treatment of Mild-to-Moderate Alzheimer's DiseaseGlobeNewsWire • 12/01/20
Athira Pharma Reports Third Quarter 2020 Financial Results and Provides Business HighlightsGlobeNewsWire • 11/12/20
Athira Pharma to Host Educational Webinar on the Predictive Nature of P300 to Determine Clinical Benefit of Alzheimer's Disease TreatmentsGlobeNewsWire • 10/21/20
Athira Pharma Announces Initiation of Patient Dosing for the LIFT-AD Study, a Phase 2/3 Clinical Trial to Evaluate ATH-1017 for Treatment of Mild-to-Moderate Alzheimer's DiseaseGlobeNewsWire • 10/01/20
Athira Pharma raises $204M in IPO, reaching ‘big milestone’ in fight against Alzheimer’s and other diseasesGeekWire • 09/18/20